Key takeaways:
Parkinson’s disease is a nerve condition that affects movement. People with Type 2 diabetes may have a greater risk of developing this nerve condition. And having diabetes can worsen Parkinson’s disease symptoms.
Researchers have been studying whether diabetes medications can be useful for managing Parkinson’s disease. Studied medications include glucagon-like peptide-1 (GLP-1) receptor agonists, such as lixisenatide (Adlyxin). Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (Jardiance), have also been studied.
Early research using GLP-1 receptor agonists for Parkinson’s disease shows positive results. But larger studies are needed to confirm these benefits.
Parkinson’s disease is a movement disorder that gets worse over time without treatment. People experience symptoms such as shaking, stiffness, or slowed movement. Over time, it can also affect your thinking and mood.
While there are treatments to help improve symptoms, there’s no known cure. And experts aren’t clear on what causes the condition. But there seems to be a connection between Parkinson’s disease and Type 2 diabetes.
People living with Type 2 diabetes may be more likely to develop Parkinson’s disease. And people with Type 2 diabetes tend to have worse Parkinson’s disease symptoms. Because of this, experts have been exploring whether certain diabetes medications could help manage Parkinson’s disease.
Need help getting GOCOVRI?
$20* Co-pay Assistance Program for commercially insured patients
If you don't have insurance, your insurance doesn't cover GOCOVRI,† or if you can't afford GOCOVRI, the Patient Assistance Program may help you get GOCOVRI at no cost.
*Terms and conditions apply.
†Financial and medical eligibility requirements vary by organization.
Will we see diabetes drugs being used for Parkinson’s disease in the future? Let’s discuss what the research says.
Good to know: Much of the research discussed in this article is focused on people who have both Type 2 diabetes and Parkinson’s disease. Information is limited regarding how the research pertains to people who have Parkinson’s disease but not diabetes.
The evidence is mixed about whether diabetes medications may work for Parkinson’s disease. As we’ll discuss below, some studies have found that certain medications might slow progression or treat symptoms. Other studies haven’t.
The medication bromocriptine (Cycloset, Parlodel) was originally FDA approved for Parkinson’s disease. Years later, it was also approved for Type 2 diabetes. So it’s not out of the question that other diabetes medications may help with Parkinson’s disease. But keep in mind that bromocriptine isn’t a commonly used medication for either condition.
One reason diabetes medications are being studied is because they help combat insulin resistance. This is when your body doesn’t respond to its natural insulin as expected. People with Type 2 diabetes often have insulin resistance. And current research suggests insulin resistance may play a role in the development and progression of Parkinson’s disease.
Several types of diabetes medications have been studied for Parkinson’s disease. Many of the studies were conducted in animals. But some were conducted with human participants.
Examples of diabetes medications that have been studied for treating Parkinson’s disease are listed in the table below. Glucagon-like peptide-1 (GLP-1) receptor agonists seem to be the medication class with the most promising results so far.
Diabetes medication name | Medication class | Results in clinical studies |
---|---|---|
Empagliflozin (Jardiance) | Sodium-glucose cotransporter-2 (SGLT2) inhibitors |
|
Exenatide (Bydureon BCise, Byetta) | GLP-1 receptor agonists |
|
Liraglutide (Victoza) | GLP-1 receptor agonists |
|
Lixisenatide (Adlyxin)* | GLP-1 receptor agonists |
|
Pioglitazone (Actos) | Thiazolidinediones, or “glitazones” |
|
Saxagliptin, linagliptin (Tradjenta) | Dipeptidyl peptidase 4 (DPP-4) inhibitors, or “gliptins” |
|
Semaglutide (Ozempic) | GLP-1 receptor agonists |
|
*Not currently available in the U.S.
Experts are still exploring if and how diabetes medications might help Parkinson’s disease symptoms. One of the biggest questions is whether these medications can help people who have Parksinon’s disease but don’t have Type 2 diabetes.
FDA-approved treatments: Learn about which Parkinson’s disease medications are currently recommended.
Dancing her way through Parkinson’s: One woman explains how she reconnected with her body through dance at age 70 — and how it helps her manage her Parkinson’s disease symptoms.
More than medication: Read about top self-care strategies that can help improve certain Parkinson’s disease symptoms.
For those who do have diabetes and Parkinson’s disease, there is promising evidence that managing your blood glucose (sugar) can be helpful in managing Parkinson’s symptoms. When diabetes is well-managed, meaning your hemoglobin A1C stays under 7%, there’s a lower risk of long-term complications. This includes less damage to the nerves in your brain. So it makes sense that diabetes medications may help with Parkinson’s disease if you also have Type 2 diabetes.
But there isn’t good evidence that taking diabetes medications can help with Parkinson’s disease if you don’t have diabetes.
There are a few theories about why diabetes medications might help Parkinson’s disease for people with diabetes. As mentioned above, combating insulin resistance is one way they may work. They may also help reduce inflammation and improve energy production in brain cells.
Here’s some more details on how some diabetes medications may help people who have both Parkinson’s disease and Type 2 diabetes:
They may reduce brain inflammation. Inflammation in the brain may play a partial role in how Parkinson’s disease develops and progresses. Some diabetes medications may reduce this inflammation. And this might protect the brain cells that are affected by the condition.
They may improve energy production from mitochondria in brain cells. Mitochondria are the parts of cells that make energy. In people with Parkinson’s, mitochondria don’t work as well, which can cause brain cells to die. Some diabetes medications can improve how mitochondria work. And this may help keep brain cells alive longer.
They help the brain use insulin. As discussed earlier, insulin resistance in the brain may be linked to Parkinson's disease in people with diabetes. Diabetes medications can improve how the brain uses insulin, which might help slow down inflammation in the body.
Keep in mind that experts are still researching this topic. Scientists don’t have a definite answer about how diabetes medications may affect Parkinson’s disease. This information will likely change as we learn more.
Right now, only bromocriptine is approved for both Parkinson’s disease and Type 2 diabetes. But it’s not a first-choice medication for either condition. Early studies of other medications show promise, particularly with GLP-1 receptor agonists.
It’s possible that we could see other diabetes medications be approved for Parkinson’s disease in the future. But more studies confirming their benefits are needed first. It would likely be several years before we hear about possible FDA approvals.
The possibility of using diabetes medications to treat Parkinson’s disease is exciting. In the future, it may offer additional options for people living with this condition.
Diabetes medications being studied for Parkinson’s disease in people with Type 2 diabetes include glucagon-like peptide-1 (GLP-1) receptor agonists, such as lixisenatide (Adlyxin). Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (Jardiance), are also being researched.
Currently, the evidence is mixed on how well these diabetes medications might work for Parkinson’s disease. More studies are needed to confirm if there are benefits and understand potential risks.
Aguirre-Vidal, Y., et al. (2024). Antidiabetic drugs in Parkinson’s disease. Clinical Parkinsonism & Related Disorders.
Athauda, D., et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: A randomised, double-blind, placebo-controlled trial. The Lancet.
Athauda, D., et al. (2022). The impact of type 2 diabetes in Parkinson’s disease. Movement Disorders.
Bantounou, M. A., et al. (2024). The association between type 2 diabetes mellitus and Parkinson's disease; A systematic review and meta-analysis. Brain Disorders.
Brauer, R., et al. (2015). Glitazone treatment and incidence of Parkinson's disease among people with diabetes: A retrospective cohort study. PLOS Medicine.
Brauer, R., et al. (2020). Diabetes medications and risk of Parkinson’s disease: A cohort study of patients with diabetes. Brain.
Kim, H. K., et al. (2024). SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes. Neurology.
Lin, Y., et al. (2023). Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson’s disease in diabetic patients. Scientific Reports.
Malatt, C., et al. (2022). Liraglutide improves non-motor function and activities of daily living in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial (P9-11.005). Neurology.
Meca, A. D., et al. (2024). Unlocking the potential: Semaglutide’s impact on Alzheimer’s and Parkinson's disease in animal models. Current Issues in Molecular Biology.
Meissner, W. G., et al. (2024). Trial of lixisenatide in early Parkinson’s disease. The New England Journal of Medicine.
Mohammed, N. N., et al. (2024). Empagliflozin repurposing in Parkinson’s disease; modulation of oxidative stress, neuroinflammation, AMPK/SIRT-1/PGC-1α, and wnt/β-catenin pathways. Inflammopharmacology.
Moon, H. P., et al. (2015). Mitochondrial dysfunction in Parkinson’s disease. Experimental Neurobiology.
National Cancer Institute. (n.d.). Mitochondria. National Institutes of Health.
Ozery, M., et al. (2024). Bromocriptine. StatPearls.
Pringsheim, T., et al. (2021). Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: A report of the AAN guideline subcommittee. Neurology.
Simuni, T., et al. (2016). Pioglitazone in early Parkinson’s disease: A phase 2, multicentre, double-blind, randomised trial. The Lancet Neurology.
Vijiaratnam, N., et al. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. The Lancet.
Zagare, A., et al. (2024). Insulin resistance is a modifying factor for Parkinson’s disease. Movement Disorders.
Zhang, W., et al. (2023). Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy.